Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901575 · ClinicalTrials.gov registry record · Phase 4
Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01901575 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 16 participants.
The verdict
NCT01901575, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin
Interventions
- DRUG Remifentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01901575
The ClinicalTrials.gov registry entry for NCT01901575 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remifentanil is the first listed.
NCT01901575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01901575 about?
NCT01901575 is a clinical study titled "Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia". Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin
What is the current status of trial NCT01901575?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2011-07. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01901575?
The interventions under investigation include: Remifentanil (DRUG).
Who is sponsoring clinical trial NCT01901575?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.